Trevi Therapeutics Share Price Today

Trevi Therapeutics holds $299M cash, extends runway into 2030

Cash position stands at $299 million, providing a runway into 2030. OCEAN-1 and OCEAN-2 trials for IPF-related chronic cough are initiated. Trevi is the sole active program in refractory chronic cough after competitor failures. Phase 2 dose-ranging study for non-IPF ILD planned for Q1 2027 start. Runway funds trials through key inflection points but excludes commercial launch costs.

Trevi Therapeutics holds $319 million cash, extending runway to 2030

Cash position stands at $319 million as of Q2 2026. Cash runway extended into 2030, unchanged from prior guidance. Initiated OCEAN-1 Phase 3 and LAKE Phase 2b clinical trials. Plans to initiate OCEAN-2 Phase 3 trial in Q3 2026. Awaiting FDA feedback on non-IPF ILD chronic cough program.

Trevi Therapeutics to present at four healthcare conferences in September 2026

Trevi Therapeutics announced senior management participation in four healthcare conferences in September 2026. Fireside chats are scheduled at the 2026 Cantor Global Healthcare Conference (September 10), H.C. Wainwright 28th Annual Global Investment Conference (September 14), and Morgan Stanley 24th Annual Global Healthcare Conference (September 15). James Cassella, Ph.D., CDO, will participate in two panel discussions at the 10th Anniversary IPF Summit on October 1, 2026 in Boston. The company is developing Haduvio (oral nalbuphine extended-release) for chronic cough in IPF, non-IPF ILD, and RCC patients, with no FDA-approved therapies currently available for these conditions. Target patient populations include approximately 140,000 U.S. IPF patients, approximately 228,000 non-IPF ILD patients, and approximately 2-3 million RCC patients in the U.S.

Trevi Therapeutics to present nalbuphine ER data at ERS Congress 2026

Trevi Therapeutics has two abstracts accepted at the ERS Congress 2026, taking place September 5-9, 2026, in Barcelona, Spain. An oral presentation by Marlies S. Wijsenbeek will cover LCQ quality-of-life data from the Phase 2b CORAL trial of nalbuphine ER in IPF-related chronic cough. A poster presentation by Imran Satia will cover LCQ quality-of-life data from the Phase 2a RIVER trial of nalbuphine ER in refractory chronic cough. The CORAL trial enrolled 165 patients across three dose groups (27 mg, 54 mg, and 108 mg twice daily) and placebo over a 6-week treatment period. Chronic cough in IPF and non-IPF ILD affects an estimated 140,000 and 228,000 U.S. patients respectively, with no FDA-approved therapies available.

Trevi Therapeutics Q2 Results: Earnings call set for Aug 6

Trevi Therapeutics, Inc. will host a conference call on August 6, 2026, to discuss Q2 2026 financial results and corporate updates. The clinical-stage biopharma firm is advancing Haduvio for chronic cough in IPF, non-IPF ILD, and RCC patients, addressing significant unmet needs with no current FDA-approved therapies.

Trevi Therapeutics to present at Oppenheimer and Stifel biotech summits

Trevi Therapeutics, Inc. confirmed management appearances at Oppenheimer's Biotech in the Berkshires on August 4 and Stifel's 2026 Biotech Summer Summit on August 10–12. CEO Jennifer Good and CFO David Hastings will discuss Haduvio, an investigational oral nalbuphine ER therapy targeting chronic cough in IPF, non-IPF ILD, and RCC patients. The drug addresses significant unmet needs in populations totaling millions of U.S. patients with no current FDA-approved treatments.